ClinicalTrials.gg
RecruitingNCT07325942Updated Jan 8, 2026

Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure

An interventional study of low-volume high intensity interval training and High volume high intensity interval training in Chronic Heart Failure, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Heart Failure by Cairo University — 3 open to participants now, 4 under way, 1 of them phase 3. Heart Failure · Cairo University.

Planned enrollment
10th of 13
45 · median 60
Started
2025
with 1 other
No phase
9 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Heart Failure by Cairo University, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 9 with no phase, and was the 12th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 13 studies in Heart Failure by Cairo University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Heart Failure by Cairo University, or all of them as a file.
02

Study summary

this study aims to investigate the effect of low vs high volume- high intensity interval training on functional capacity and quality of life in chronic heart failure patients

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chronic stable heart failure patient with reduced (EF \<40)
  2. Age Above 18 years old
  3. Both males and females
  4. The ability to provide

Exclusion criteria

Exclusion Criteria:

  1. Based on the Scientific Statement from the American Heart Association: for exercise Testing and Training. (Fletcher et al., 2013)

    1. Acute myocardial infarction (MI), within 2 days
    2. Ongoing unstable angina
    3. Uncontrolled cardiac tachy or brady arrhythmia with hemodynamic compromise
    4. Active endocarditis
    5. Symptomatic severe aortic stenosis
    6. Decompensated heart failure
    7. Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis
    8. Acute myocarditis or pericarditis
    9. Acute aortic dissection
    10. Physical disability that precludes safe and adequate testing or training
    11. Known obstructive left main coronary artery stenosis
    12. Hypertrophic obstructive cardiomyopathy with severe resting gradient
    13. Recent stroke or
    14. Mental impairment with limited ability to cooperate
    15. Resting hypertension with systolic or diastolic blood pressures >200/110 mmHg
    16. Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, and hyperthyroidism
  2. Acute decompensated heart failure class IV
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Low volume high intensity interval training

    This group will receive the usual care (standard medical treatment) in addition to LV-HIIT on a treadmill for 8 weeks, 2 sessions per week.

    Other: low-volume high intensity interval training · Drug: Standard medical treatment

  • Experimental
    high volume high intensity interval training

    In this group, the patients will receive the usual care (standard treatment) in addition to HV-HIIT on a treadmill for 8 weeks, 2 sessions per week

    Other: High volume high intensity interval training · Drug: Standard medical treatment

  • Other
    control group

    It includes 15 patients who will receive standard medical treatment only

    Drug: Standard medical treatment

Interventions

  • Otherlow-volume high intensity interval training

    Low-volume HIIT (LV-HIIT) is a particularly time-efficient subtype of interval training, which has gained increasing attention in recent years. As per the previous definition, these brief training protocols typically involve≤10 min of intense exercise within a session lasting≤30 min including warm-up, recovery phases between intervals, and cool-down

  • OtherHigh volume high intensity interval training

    long (2-4 min) bouts of high (not maximum) intensity exercise interspersed with recovery periods which have wide varieties in the protocols according to the intensity, duration, and number of intervals performed

  • DrugStandard medical treatment

    standard medical treatment for chronic heart failure as per international guidlines

06

What researchers measure

Primary outcomes

  1. 6 minute walk test

    self-paced submaximal field exercise test to assess submaximal functional capacity of the patient , the distance walked by the patient for six minutes will be measured by meters

    Time frame: at enrolment and at the end of treatment at 8 weeks

  2. 2D Echocardiographic parameters

    Left ventricle geometry: left ventricular end-diastolic diameter (LVEDD) mm, left ventricular end-systolic diameter (LVESD) mm, left ventricular end-systolic volume (LVESV) ml. and, left ventricular end-diastolic volume (LVEDV) ml. Left ventricle Systolic function: left ventricular ejection fraction (LVEF) % Left ventricle Diastolic function :E wave cm/s: early diastolic mitral inflow velocity, A wave cm/s: diastolic mitral inflow velocity during late atrial contraction , E/A ratio

    Time frame: at enrollment and at the end of treatment at 8 weeks

Secondary outcomes

  1. Minnesota living with heart failure questionnaire (MLHFQ)

    The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is the tool most widely used and recognized to assess HRQOL in adults with Hf, was developed in 1987 by Thomas Rector, focusing on the underlying relationship between pathophysiology, symptoms, functional limitations, and psychological distress, it measures the impacts of symptoms and treatment on different dimensions of HRQOL in HF patients.

    Time frame: at enrollment and at the end of treatment at 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jun 2026, 5 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 5 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 8, 2026
StartEst.
Dec 10, 2025
Primary completionEst.
Jun 6, 2026
CompletionEst.
Jun 6, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07325942
Lead sponsor
Cairo University
Responsible party
Aya Ibrahim Elshenawy Elshenawy (physical therapy specialist, Cairo University) — Principal investigator
First posted
Jan 8, 2026
Start date
Dec 10, 2025 (estimated)
Primary completion
Jun 6, 2026 (estimated)
Completion
Jun 6, 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Aya I Elshenawy
Contact
dr.aya_ebrahime@yahoo.com
+01098811085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion